Sustained Delivery of Timolol Maleate for Over 90 Days by Subconjunctival Injection.

ABSTRACT:

Purpose

Medical treatment of glaucoma relies on intraocular pressure (IOP)-lowering medications, typically administered daily by the patient. While these medications are effective when applied correctly, patient adherence is a major obstacle in glaucoma treatment. We have developed a sustained-release formulation of timolol maleate that can be injected subconjunctivally to avoid patient noncompliance.

Methods

A biodegradable microsphere formulation for timolol maleate was injected subconjunctivally in normal rabbits. We measured timolol levels in tears, aqueous humor, vitreous humor, and serum of study rabbits. Furthermore, IOP profiles were recorded longitudinally. Tissue compatibility and side effects were evaluated using histochemistry.

Results

The microsphere form

SUBMITTER: Lavik E 

PROVIDER: S-EPMC5165680 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature